2.8.2008 - Reata to Present at 2008 BIO CEO and Investor Conference on 2/11 at 2:00 pm

Reata to Present at BIO CEO and Investor Conference 2008

Presentation Scheduled for Monday, February 11 at 2:00 EST

IRVING, TX -- February 8, 2008 -- Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, will be presenting a company overview on Monday, February 11, 2008 at the Biotechnology Industry Organization's CEO and Investor Conference at 2:00 p.m., Eastern Time. The presentation will include an update on the company's portfolio of clinical development programs as well as its best-in-class protein folding discovery platform.

The company review will highlight clinical data on RTA 402, an orally available, first-in-class Antioxidant Inflammation Modulator (AIM) in Phase 2 development for cancer, renal dysfunction, and rheumatoid arthritis. Mr. Huff will also share data on other AIMs targeting major inflammatory indications. An update will also be provided on berubicin (also known as RTA 744), a novel anthracycline in Phase 2 development for brain metastases. Each of these drugs targets areas of substantial unmet medical need and has significant commercial potential. Lastly, Mr. Huff will provide an update on the progress the company has made in identifying small molecule drugs that correct protein misfolding. Using Reata's best-in-class assay, the company has succeeded in identifying a small molecule drug that rescues the misfolded SOD1, a protein implicated in the development of amyotrophic lateral sclerosis, known more commonly as Lou Gehrig's disease.

About Reata

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases. The company's two lead programs are in advanced clinical trials for deadly, late-stage cancers and proof of concept studies in inflammatory diseases. In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform based around the use of small molecule molecular chaperones to correct protein misfolding. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Founded in 2002, Reata is based in theDallasarea. For more information, visit www.reatapharma.com